Novo Nordisk A/S - NVO Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NVO shares.
View NVO analyst ratings or view top-rated stocks.

17 Wall Street analysts have issued 12-month price targets for Novo Nordisk A/S's shares. Their NVO share price forecasts range from $130.00 to $900.00. On average, they expect the company's stock price to reach $717.14 in the next twelve months. This suggests a possible upside of 465.1% from the stock's current price.
View analysts price targets for NVO or view top-rated stocks among Wall Street analysts.

Novo Nordisk A/S's stock was trading at $112.00 at the start of the year. Since then, NVO shares have increased by 13.3% and is now trading at $126.90.
View the best growth stocks for 2022 here.

Novo Nordisk A/S saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 2,650,000 shares, a decrease of 17.7% from the October 15th total of 3,220,000 shares. Based on an average trading volume of 1,570,000 shares, the short-interest ratio is presently 1.7 days. Approximately 0.2% of the shares of the stock are sold short.
View Novo Nordisk A/S's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our NVO earnings forecast.

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Wednesday, November, 2nd. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.02. The firm earned $6.17 billion during the quarter, compared to analysts' expectations of $6.09 billion. Novo Nordisk A/S had a net margin of 31.57% and a trailing twelve-month return on equity of 72.57%.

Novo Nordisk A/S announced a semi-annual dividend on Friday, August 5th. Shareholders of record on Monday, August 15th will be paid a dividend of $0.5836 per share on Tuesday, August 23rd. This represents a dividend yield of 1.1%. The ex-dividend date is Friday, August 12th.
Read our dividend analysis for NVO.

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $0.81 per share and currently has a dividend yield of 0.64%. The dividend payout ratio is 24.04%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 20.25% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

Novo Nordisk A/S issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $23.66 billion-$24.23 billion, compared to the consensus revenue estimate of $22.97 billion.

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.68%), Jennison Associates LLC (0.48%), Fisher Asset Management LLC (0.41%), Fayez Sarofim & Co (0.23%), BlackRock Inc. (0.21%) and Folketrygdfondet (0.19%).
View institutional ownership trends.

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVO stock can currently be purchased for approximately $126.90.

Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $287.17 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.37 on an earnings per share basis.

The company employs 45,000 workers across the globe.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for the company is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.